ORYZON GENOMICS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.06 EUR | +1.48% |
|
+4.57% | +9.11% |
| 05-06 | Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-22 | Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 127M | - | - | - | - | - | |
| 49.46B | - | |||||
| 42.58B | ||||||
| 42.49B | ||||||
| 29.09B | ||||||
| 26.61B |
- Stock Market
- Equities
- ORY Stock
- Charts Oryzon Genomics S.A.
- Sector Chart